Science 3366086 1268-1273 2012.Viaud S Daillere S Boneca IG Lepage P Langella P Chamaillard M Pittet MJ Ghiringhelli F Trinchieri G Goldszmid R and Zitvogel L Gut microbiome and anticancer immune response really hot Sht Cell Death Differ 222 199- 214 2015.Boursi B Mamtani R Haynes K and Yang YX Recurrent antibiotic exposure may promote cancer formation-another step in understanding the role of the human microbiota Eur J Cancer 5117 2655-2664 2015.Iida N Dzutsev A Stewart CA Smith L Bouladoux N Weingarten RA Molina DA Salcedo R Back T Cramer S Dai RM Kiu H Cardone M Naik S Patri AK Wang E Marincola FM Frank KM Belkaid Y Trinchieri G and Goldszmid RS Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.

Science 3426161 967-970 2013.Viaud S Saccheri F Mignot G Yamazaki T Daillere R Hannani D Enot DP Pfirschke C Engblom C Pittet MJ Schlitzer A Ginhoux F Apetoh L Chachaty E Woerther PL Eberl G Berard M Ecobichon C Clermont D Bizet C Gaboriau-Routhiau V Cerf-Bensussan N Opolon P Yessaad N Vivier E Ryffel B Elson CO Dore J Kroemer G Lepage P Boneca IG Ghiringhelli F and Zitvogel L The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.

Curr Oncol 19Suppl 1 S52-S58 2012.Brahmer J Reckamp KL Baas P Crino L Eberhardt WE Poddubskaya E Antonia S Pluzanski A Vokes EE Holgado E Waterhouse D Ready N Gainor J Aren Frontera O Havel L Steins M Garassino MC Aerts JG Domine M Paz-Ares L Reck M Baudelet C Harbison CT Lestini B and Spigel DR Nivolumab versus docetaxel in advanced squamous-cell non- small-cell lung cancer.

N Engl J Med 3732 123-135 2015.Borghaei H Paz-Ares L Horn L Spigel DR Steins M Ready NE Chow LQ Vokes EE Felip E Holgado E Barlesi F Kohlhaufl M Arrieta O Burgio MA Fayette J Lena H Poddubskaya E Gerber DE Gettinger SN Rudin CM Rizvi N Crino L Blumenschein GR Jr. Antonia SJ Dorange C HarbisonCT Graf Finckenstein F and Brahmer JR Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.

Science 3506264 1084-1089 2015.Derosa L Routy B Enot D Baciarello G Massard C Loriot Y Fizazi K Escudier BJ Zitvogel L and Albiges L Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.

ASCO GU Poster session 2017.Eisenhauer EA Therasse P Bogaerts J Schwartz LH Sargent D Ford R Dancey J Arbuck S Gwyther S Mooney M Rubinstein L Shankar L Dodd L Kaplan R Lacombe D and Verweij J New response evaluation criteria in solid tumours Revised RECIST guideline version 1.1.

Eur J Cancer 452 228-247 2009.Daillere R Vetizou M Waldschmitt N Yamazaki T Isnard C Poirier-Colame V Duong CP Flament C Lepage P Roberti MP Routy B Jacquelot N Apetoh L Becharef S Rusakiewicz S Langella P Sokol H Kroemer G Enot D Roux A Eggermont A Tartour E Johannes L Woerther PL Chachaty E Soria JC Golden E Formenti S Plebanski M Madondo M Rosenstiel P Raoult D Cattoir V Boneca IG Chamaillard M and Zitvogel L Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects.

It has been shown that imbalance of microbiota ecosystem caused by repeated exposure to antibiotic can increase the frequency of some types of cancer such as lung cancer suggesting a relationship between microbiota and carcinogenesis 10.

This difference linked to microbiota was immune-mediated with tumor-specific T-cell responses and intratumoral CD8 T-cell infiltration significantly higher in mice with Bifidobacterium in commensal microbiota.

It is in this case that microbiota and more precisely gut microbiota can play an important role.

